Toggle navigation
Search
Tree View
MeSH on Demand
MeSH 2025
About
Suggestions
Contact Us
Daclizumab
MeSH Descriptor Data 2024
Details
Qualifiers
MeSH Tree Structures
Concepts
MeSH Heading
Daclizumab
Tree Number(s)
D12.776.124.486.485.114.224.060.766
D12.776.124.790.651.114.224.060.766
D12.776.377.715.548.114.224.200.766
Unique ID
D000077561
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000077561
Scope Note
An anti-TAC (
INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT
) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of
ACUTE RELAPSING MULTIPLE SCLEROSIS
.
Entry Term(s)
Dacliximab
Ro 24-7375
Ro-24-7375
Zenapax
Zinbryta
Pharm Action
Immunosuppressive Agents
Registry Numbers
CUJ2MVI71Y
0
Related Numbers
152923-56-3
Public MeSH Note
2019; DACLIZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2012-2018; and under ANTIBODIES, MONOCLONAL 1995-2011
History Note
2019 (1995)
Date Established
2019/01/01
Date of Entry
2018/07/09
Revision Date
2018/04/09
Allowable Qualifiers
administration & dosage (AD)
adverse effects (AE)
analysis (AN)
biosynthesis (BI)
blood (BL)
cerebrospinal fluid (CF)
chemistry (CH)
classification (CL)
drug effects (DE)
economics (EC)
genetics (GE)
history (HI)
immunology (IM)
isolation & purification (IP)
metabolism (ME)
pharmacokinetics (PK)
pharmacology (PD)
physiology (PH)
poisoning (PO)
radiation effects (RE)
therapeutic use (TU)
toxicity (TO)
ultrastructure (UL)
urine (UR)
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Antibodies [D12.776.124.486.485.114]
Antibodies, Monoclonal [D12.776.124.486.485.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
Abciximab [D12.776.124.486.485.114.224.060.125]
Adalimumab [D12.776.124.486.485.114.224.060.250]
Alemtuzumab [D12.776.124.486.485.114.224.060.313]
Basiliximab [D12.776.124.486.485.114.224.060.344]
Bevacizumab [D12.776.124.486.485.114.224.060.375]
Brentuximab Vedotin [D12.776.124.486.485.114.224.060.438]
Certolizumab Pegol [D12.776.124.486.485.114.224.060.500]
Cetuximab [D12.776.124.486.485.114.224.060.750]
Daclizumab [D12.776.124.486.485.114.224.060.766]
Denosumab [D12.776.124.486.485.114.224.060.782]
Gemtuzumab [D12.776.124.486.485.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.486.485.114.224.060.794]
Ipilimumab [D12.776.124.486.485.114.224.060.798]
Natalizumab [D12.776.124.486.485.114.224.060.813]
Nivolumab [D12.776.124.486.485.114.224.060.829]
Omalizumab [D12.776.124.486.485.114.224.060.844]
Palivizumab [D12.776.124.486.485.114.224.060.860]
Panitumumab [D12.776.124.486.485.114.224.060.864]
Ramucirumab [D12.776.124.486.485.114.224.060.866]
Ranibizumab [D12.776.124.486.485.114.224.060.868]
Trastuzumab [D12.776.124.486.485.114.224.060.875]
Ustekinumab [D12.776.124.486.485.114.224.060.937]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Antibodies, Monoclonal [D12.776.124.790.651.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
Abciximab [D12.776.124.790.651.114.224.060.125]
Adalimumab [D12.776.124.790.651.114.224.060.250]
Alemtuzumab [D12.776.124.790.651.114.224.060.375]
Basiliximab [D12.776.124.790.651.114.224.060.407]
Bevacizumab [D12.776.124.790.651.114.224.060.438]
Brentuximab Vedotin [D12.776.124.790.651.114.224.060.469]
Certolizumab Pegol [D12.776.124.790.651.114.224.060.500]
Cetuximab [D12.776.124.790.651.114.224.060.750]
Daclizumab [D12.776.124.790.651.114.224.060.766]
Denosumab [D12.776.124.790.651.114.224.060.782]
Gemtuzumab [D12.776.124.790.651.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.790.651.114.224.060.794]
Ipilimumab [D12.776.124.790.651.114.224.060.798]
Natalizumab [D12.776.124.790.651.114.224.060.813]
Nivolumab [D12.776.124.790.651.114.224.060.829]
Omalizumab [D12.776.124.790.651.114.224.060.844]
Palivizumab [D12.776.124.790.651.114.224.060.860]
Panitumumab [D12.776.124.790.651.114.224.060.864]
Ramucirumab [D12.776.124.790.651.114.224.060.866]
Ranibizumab [D12.776.124.790.651.114.224.060.868]
Trastuzumab [D12.776.124.790.651.114.224.060.875]
Ustekinumab [D12.776.124.790.651.114.224.060.937]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Antibodies, Monoclonal [D12.776.377.715.548.114.224]
Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Abciximab [D12.776.377.715.548.114.224.200.125]
Adalimumab [D12.776.377.715.548.114.224.200.250]
Alemtuzumab [D12.776.377.715.548.114.224.200.375]
Basiliximab [D12.776.377.715.548.114.224.200.407]
Bevacizumab [D12.776.377.715.548.114.224.200.438]
Brentuximab Vedotin [D12.776.377.715.548.114.224.200.469]
Certolizumab Pegol [D12.776.377.715.548.114.224.200.500]
Cetuximab [D12.776.377.715.548.114.224.200.750]
Daclizumab [D12.776.377.715.548.114.224.200.766]
Denosumab [D12.776.377.715.548.114.224.200.782]
Gemtuzumab [D12.776.377.715.548.114.224.200.790]
Inotuzumab Ozogamicin [D12.776.377.715.548.114.224.200.794]
Ipilimumab [D12.776.377.715.548.114.224.200.798]
Natalizumab [D12.776.377.715.548.114.224.200.813]
Nivolumab [D12.776.377.715.548.114.224.200.829]
Omalizumab [D12.776.377.715.548.114.224.200.844]
Palivizumab [D12.776.377.715.548.114.224.200.860]
Panitumumab [D12.776.377.715.548.114.224.200.864]
Ramucirumab [D12.776.377.715.548.114.224.200.866]
Ranibizumab [D12.776.377.715.548.114.224.200.868]
Trastuzumab [D12.776.377.715.548.114.224.200.875]
Ustekinumab [D12.776.377.715.548.114.224.200.937]
Expand All
Collapse All
Daclizumab
Preferred
Concept UI
M0252703
Registry Numbers
CUJ2MVI71Y
Related Numbers
152923-56-3
Scope Note
An anti-TAC (
INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT
) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of
ACUTE RELAPSING MULTIPLE SCLEROSIS
.
Terms
Daclizumab
Preferred Term
Term UI
T000940276
Date
02/09/2018
LexicalTag
NON
ThesaurusID
Dacliximab
Term UI
T000940277
Date
02/09/2018
LexicalTag
NON
ThesaurusID
NLM (2013)
Ro 24-7375
Narrower
Concept UI
M0252700
Registry Numbers
0
Terms
Ro 24-7375
Preferred Term
Term UI
T282705
Date
01/01/1955
LexicalTag
LAB
ThesaurusID
NLM (1995)
Ro-24-7375
Term UI
T282706
Date
01/01/1955
LexicalTag
LAB
ThesaurusID
NLM (1995)
Zenapax
Narrower
Concept UI
M0252702
Registry Numbers
0
Terms
Zenapax
Preferred Term
Term UI
T282707
Date
01/01/1955
LexicalTag
TRD
ThesaurusID
Zinbryta
Narrower
Concept UI
M000622365
Registry Numbers
0
Terms
Zinbryta
Preferred Term
Term UI
T000908612
Date
10/03/2016
LexicalTag
TRD
ThesaurusID
NLM (2017)
page delivered in 0.171s